Law360
Defending ‘Salt’ Patents In Hatch-Waxman Cases
December 1, 2015
After Pfizer Inc. v. Apotex Inc., 480 F.3d 1348 (Fed. Cir. 2007), reh’g denied, 488 F.3d 1377 (Fed. Cir. 2007) (“Norvasc decision”), there was an apparent drop in cases involving salt patents, i.e., which claim a particular salt form of a drug. However, several recent cases have upheld salt patents, and this article will discuss potential responses to some common challenges, namely a Petering anticipation challenge, and a KSR obvious-to-try challenge.
Capabilities
Suggested News & Insights
Patent Trial and Appeal Board (PTAB) Update: Director Returns Merits-Based Considerations to the PTABNovember 18, 2026Sidley Represents Dechra in Acquisition of Gallant PetNovember 18, 2026Sidley to Add Premier Cross-Practice Group of More Than 35 Weil Lawyers in Its New York OfficeNovember 18, 2026Q&A: How Sidley’s Patent Team Stays Ahead of the AI GameOctober 12, 2026When the Meeting Minutes and the AI Transcript Don’t Match: Litigation Insights From Delaware ChancerySeptember 17, 202622 Sidley Lawyers Named to 2027 Lawdragon 500 Leading Litigators in AmericaSeptember 11, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory